

Amendments to the Claims:

Claims 1-4 (Cancelled)

Claim 5. (Currently amended) A method of inducing apoptosis in a cell in a mammal diagnosed as having a proliferative disease, said method comprising administering to said mammal ~~an~~ a modified antisense ~~nucleic acid~~ oligonucleotide of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity, wherein said antisense ~~nucleic acid~~ oligonucleotide is complementary to a portion of human X-linked IAP (XIAP) (SEQ ID NO:3).

Claims 6-8 (Cancelled)

Claim 9. (Currently amended) A method of treating a patient diagnosed as having a proliferative disease, said method comprising administering to said patient ~~an~~ a modified antisense ~~nucleic acid~~ oligonucleotide of length sufficient to inhibit an inhibitor of apoptosis (IAP) biological activity, wherein said antisense ~~nucleic acid~~ oligonucleotide is complementary to a portion of human X-linked IAP (XIAP) (SEQ ID NO:3).

Claim 10. (Previously presented) The method of claim 9, wherein said mammal is a human.

Claim 11. (Previously presented) The method of claim 9, wherein said proliferative disease is cancer.

Claim 12. (Previously presented) The method of claim 11, wherein said cancer is ovarian cancer, adenocarcinoma, lymphoma, or pancreatic cancer.

Claim 13. (Previously presented) The method of claim 5, wherein said mammal is a human.

Claim 14. (Previously presented) The method of claim 5, wherein said proliferative disease is cancer.

Claim 15. (Previously presented) The method of claim 14, wherein said cancer is ovarian cancer, adenocarcinoma, lymphoma, or pancreatic cancer.

Claim 16. (New) The method of claim 5, wherein said modified antisense oligonucleotide is a phosphorothioate modified oligonucleotide.